CA-ENCHROMA
EnChroma® — creators of glasses for color blindness — today announced that organizations and businesses can now sign up to support International Color Blindness Awareness Month™ 2024. Every September, hundreds of organizations come together to promote ‘color accessibility’ and inclusion for the one in 12 men (8%) and one in 200 women (.5%) who are color blind; an estimated 13 million in the United States; 30 million in Europe; and 350 million worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716891549/en/
Depiction of red-green color blind and normal color vision views of colorful buildings in Amsterdam. (Photo: Business Wire)
Anytime in September, hundreds of museums, universities, businesses, libraries, schools, park systems, tourism agencies, philanthropic groups and others will make social media posts, disseminate information, and engage in other activities to educate the public about the prevalence and effects of Color Vision Deficiency (CVD).
“Awareness of just how common color blindness is and how significant its impacts are, still remains low amongst employers, educators, parents and the general public,” said Erik Ritchie, CEO of EnChroma. “From color confusion in the workplace, at school, when enjoying sports and the outdoors, or when simply doing daily activities can be frustrating for those with CVD. This year, we hope even more organizations will support International Color Blindness Awareness Month to both educate and advocate on behalf of the color blind.”
While people with normal color vision see over one million shades of color, the red-green color blind only see an estimated 10% of hues and shades. As a result, colors can appear dull, indistinct and difficult to discern; red can appear brown; green can look tan, gray or yellow; and purple and blue look similar.
Click here to see more images depicting color blindness.
Last year, over 250 organizations around the world used their voices and platforms in support including multinational corporations such as Honeywell Aerospace, Siemens Energy and Faber-Castell; renowned museums such as the Centre Pompidou and the Georgia O’Keeffe Museum; universities such as the University of North Carolina, Boston University and North Carolina State University; state and national parks such as Friends of Kauai Wildlife Refuges and Alaska State Parks; the Atlanta Botanical Garden; nature advocates like the Audubon Nature Institute; and groups such as Travel Oregon, Lions and Kiwanis clubs, and the Boy Scouts of America.
How to Apply
Organizations and businesses can sign up here to commit to making at least one social media post, or undertake any other activity, that promotes color blindness awareness in September, using any of an array of customizable images and templates. Do as little as make one social media post using a customizable template or create your own post(s) with easy-to-use tools. Participating organizations can choose to receive two pairs of EnChroma glasses to give away to color blind students, customers, staff or visitors. The offer to give away EnChroma glasses is not available to individuals.
EnChroma Color Accessibility Program™
EnChroma is the lead advocate for ‘color accessibility,’ helping more than 400 universities, K-12 schools, state and national parks, libraries, museums, tourism departments, attractions and other organizations purchase and loan EnChroma glasses to color blind students and guests. EnChroma donates a pair of glasses for each pair an organization buys to lend to the public or students. The program is also open to employers. Scenic viewers adapted for the color blind are also available and in use by park systems across 25 states.
EnChroma glasses are engineered with special optical filters that help the red-green color blind experience an expanded range of colors more vibrantly and distinctly to make schoolwork that involves color, art, nature and other experiences more ‘color accessible.’ The glasses do not deliver full color vision and results and reaction times vary. EnChroma glasses enhance color for approximately 80% of people with deuteranomalous or protanomalous red-green color blindness who have all three of their color sensing cones. Read this study by UC Davis about the glasses.
About EnChroma
Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for red-green color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with red-green color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance. Call 510-497-0048 or visit enchroma.com for more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716891549/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
